Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Product Briefs

This article was originally published in The Gray Sheet

Executive Summary

Product announcements from Medtronic, Alere, St. Jude Medical and Integrum.

You may also be interested in...



New Hope For Amputees: OPRA Prosthetic Gets FDA Nod

The Osseoanchored Prostheses for the Rehabilitation of Amputees Implant System – or OPRA – anchors to an amputee’s thigh bone, allowing it to be used in patients for whom conventional socketed prosthetics don’t work.

Medtronic Advances Minimally Invasive Lung Cancer Diagnosis With New Interventional Lung Biopsy System

With the recent FDA approval of Medtronic's GenCut core biopsy system, the company is moving closer to its vision of diagnosing and treating lung cancer with a completely non-invasive, outpatient solution. GenCut is specifically designed for the unique challenges of lung biopsy/sampling lung lesions and allows physicians to capture larger pieces of lung tissue to be preserved for more in-depth and accurate testing and personalized care when used during bronchoscopy procedures.

Alere Flu Test Wins First CLIA Waiver For Nucleic Acid Assay

Alere’s i Influenza A & B test was granted a CLIA waiver Jan. 6, a step toward moving traditionally complex molecular diagnostics to a wider array of testing settings.

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT034054

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel